Ophthalmoplegic migraine: amelioration by Flufenamic acid, a prostaglandin inhibitor.

Abstract

It was recently suggested that prostaglandins' release (especially PGE1 and PGF2alpha) play a key role in the development of the migrainous attack. Based on this hypothesis a therapeutic trial with flufenamic acid (a prostaglandin inhibitor of the fenamates group) was conducted during 1 year in 5 patients suffering from recurrent ophthalmoplegic migraine. We treated 25 migrainous attacks; in 22 of them the patients reported marked alleviation of the headaches and only in two occasions a partial third nerve palsy accompanied the attack.

• Authors: J M Rabey, Y Vardi, D Van Dyck, M Streifler
• Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (Ophthalmologica) Vol. 175 Issue 3 Pg. 148-52 ( 1977) ISSN: 0030-3755 [Print] Switzerland
• PMID: 331178 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Prostaglandins
• Flufenamic Acid

Topics

• Adolescent
• Adult
• Clinical Trials as Topic
• Drug Evaluation
• Female
• Flufenamic Acid (therapeutic use)
• Follow-Up Studies
• Humans
• Male
• Migraine Disorders (complications, drug therapy, physiopathology)
• Ophthalmoplegia (complications, physiopathology)
• Prostaglandins (physiology)